High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
复制标题
DOI：
10.1200/jco.1997.15.2.445
复制
发表时间：
1997-02-01
影响因子：
45.3
通讯作者：
Armitage, JO
中科院分区：
文献类型：
--
作者：
Bierman, PJ;Vose, JM;Armitage, JO
目的：本研究评估了高剂量治疗后自体骨髓或外周血干细胞移植治疗滤泡性低级别非霍奇金淋巴瘤的结果。患者和方法：我们对1983年4月22日至1993年12月31日期间接受自体移植治疗滤泡性低级别淋巴瘤的100例患者进行了回顾性分析。结果：67例患者存活，48例无失败。存活患者的中位随访时间为2.6年（范围1.0 ~ 11.7年）。移植后100天内有8例（8%）死亡。另外6名患者在移植后912天内死于非复发原因。4年总生存率估计为65%(95%置信区间[CI]， 54%至75%)，无失败生存率估计为44% （95% CI， 33%至55%）。在无故障生存曲线中没有明确的平台期证据。唯一与总生存率和无衰竭生存率显著相关的因素是移植前接受化疗方案的次数。滤泡小切割细胞淋巴瘤和滤泡混合性淋巴瘤患者的预后无显著差异，接受外周血干细胞移植和未清除的自体骨髓移植患者的预后无显著差异。结论：对滤泡性低级别淋巴瘤进行大剂量治疗和自体造血修复后，延长无衰竭生存期是可能的。目前尚不清楚这种疗法是否能治愈患者，或者是否能延长患者的生存期。(C) 1997年由美国临床肿瘤学会。
Purpose: This study evaluated the results of high-dose therapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follicular low-grade non-Hodgkin's lymphoma.Patients and Methods: We performed a retrospective review of 100 patients undergoing autologous transplantation for follicular low-grade lymphoma between April 22, 1983 and December 31, 1993.Results: Sixty-seven patients remained alive and 48 were failure-free. The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7). There were eight (8%) deaths within 100 days of transplantation. Six additional patients died of nonrelapse causes up to 912 days after transplantation. Overall survival at 4 years wets estimated to be 65% (95% confidence interval [CI], 54% to 75%) and failure-free survival was estimated to be 44% (95% CI, 33% to 55%). There was no definite evidence of a plateau in the failure-free survival curve. The only factor significantly associated with overall survival and failure-free survival was the number of chemotherapy regimen received before transplantation. No significant differences in outcome were observed between patients with follicular small cleaved-cell lymphoma and follicular mixed lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone marrow transplants.Conclusion: Prolonged failure-free survival is possible following high-dose therapy and autologous hematopoietic rescue for follicular low-grade lymphoma. It is unclear whether patients are cured with this therapy or if survival is prolonged. (C) 1997 by American Society of Clinical Oncology.